Sanofi-aventis Enters into Research Collaboration with Columbia University to Develop New Diabetes Treatments anofi-aventis announced a research collaboration with Columbia University Medical Center for the development of innovative diabetes medicines. [Columbia University Press Release] Cambridge Launches New Pancreatic Cancer Centre The new Cambridge Pancreatic Cancer Centre, a multi-disciplinary centre of excellence which aims to bring cutting-edge pancreatic research from the bench to the bedside, was launched. The Centre will focus on conducting world-class human clinical trials of therapies and diagnostics which have shown scientific potential. [University of Cambridge Press Release] Pancreatic Cancer Action Network and AACR Award Research Grants Totaling Nearly $3 Million The Pancreatic Cancer Action Network and the American Association for Cancer Research (AACR) awarded 10 grants to outstanding scientists throughout the country, supporting their innovative research in the field of pancreatic cancer. [American Association for Cancer Research Press Release] Pancreatic Cancer Action Network – AACR Pathway to Leadership Grants Awarded to Early-Career Investigators The Pancreatic Cancer Action Network and the American Association for Cancer Research (AACR) have awarded Jennifer M. Bailey, Ph.D., and E. Scott Seeley, M.D., Ph.D., the 2011 Pancreatic Cancer Action Network – AACR Pathway to Leadership Grants. [American Association for Cancer Research Press Release] Scientists Awarded Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research Grants The American Association for Cancer Research (AACR) is pleased to announce the recipients of the 2011 Caring for Carcinoid Foundation-AACR Grants for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research and the 2011 Raymond and Beverly Sackler AACR Fellowships for Ileal Carcinoid Tumor Research. [American Association for Cancer Research Press Release] Adamis Reports APC-300 Kills Human Pancreatic Cancer Cells Adamis Pharmaceuticals Corporation announced that in addition to its activity in prostate cancer, its drug APC-300 significantly inhibits the growth of pancreatic cancer cells. [BusinessWire] Oramed Successfully Completes Toxicity Study For ORMD-0801 Oramed Pharmaceuticals Inc. announced that it has successfully completed a comprehensive toxicity study for its flagship oral insulin capsule, ORMD-0801. [Oramed Pharmaceuticals Inc. Press Release] XOMA 052 Phase IIb Top Line Results: Glucose Control Not Demonstrated, Positive Anti-Inflammatory Effect, Cardiovascular Biomarker and Lipid Improvement and Safety Confirmed XOMA Ltd. announced that its Phase IIb trial of XOMA 052 in Type 2 diabetes patients did not achieve the primary endpoint of reduction in glycosylated hemoglobin, or HbA1c, after six monthly treatments with XOMA 052 compared to placebo. [XOMA Ltd. Press Release] Second Lucentis Phase III Study Meets Primary Endpoint for Improved Vision in Patients with Diabetic Macular Edema Genentech, a member of the Roche Group, announced that the second of two Phase III trials evaluating Lucentis® (ranibizumab injection) in patients with diabetic macular edema met its primary endpoint. [Genentech, Inc. Press Release] Cancer Research and the $90 Billion Metaphor Although the “War on Cancer” metaphor has been a target for skeptics, who note that cancer incidence and mortality rates haven’t changed fundamentally, if one sets aside the rhetoric, it’s evident that the cancer campaign has changed therapy and saved lives, as demonstrated in this infographic Science has created of indicators for the seven deadliest cancers. [Science] |